Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
An Ehrlichia muris-like (EML) bacterium was recently detected in humans and Ixodes scapularis ticks in Minnesota and Wisconsin. The reservoir for this agent is unknown. To investigate the occurrence of the EML agent, groEL PCR testing and sequencing was performed on blood from small mammals and white-tailed deer that were collected in areas where human and tick infections were previously demonstrated. DNA of the EML agent was detected in two Peromyscus leucopus of 146 small mammals (1.4%); while 181 O. virginianus tested negative. This report provides the first evidence that DNA from the EML agent is found in P. leucopus, the same animal that is a reservoir for Anaplasma phagocytophilum in this region. The role of white-tailed deer remains inconclusive. Further sampling is warranted to understand the spatial and temporal distribution, transmission and maintenance of this pathogen.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ttbdis.2014.11.006 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Statins for polycystic ovary syndrome in varying resource settings: a phenome-wide association study and evidence synthesis.
Front Pharmacol
August 2025
Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, TN, United States.
Background: There are many diseases prevalent around the globe that lack accessible and safe treatment options. Through Vanderbilt University Medical Center's and Repurposing Essential Medicines Internationally program (Project Remedi), we aim to identify novel therapeutic uses for medications already approved and on the World Health Organization's (WHO) Essential Medicines List (EML). We explored additional uses for simvastatin, an oral 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor that is on the EML and may have additional therapeutic use outside of hypercholesterolemia.
View Article and Find Full Text PDFModeling neurotropic virus infection with functional human neural spheroids as a platform for high-throughput antiviral screening and pathogenesis.
Antiviral Res
October 2025
Division of Preclinical Innovation, National Center for Advancing Translational Sciences (NCATS), National Institutes of Health, 9800 Medical Center Drive, Rockville, MD, 20850, USA. Electronic address:
Neurotropic arboviruses pose significant threats to human health due to their ability to infect the central nervous system (CNS). Despite the significant impact on public health, mechanisms underlying neuropathogenesis remains poorly understood, and the development of effective antivirals has been hampered by the lack of predictive, high-throughput (HT) infection platforms that can replicate in vivo disease features to drive early drug discovery. To address this gap, we developed a human-based, HT-compatible, functional viral disease neural spheroid model assembled from human induced pluripotent stem cell (hiPSC)-differentiated neurons and astrocytes as a platform for studying virus infection and the development of HT screening (HTS)-compatible assays for drug discovery.
View Article and Find Full Text PDFDereplication of Sesquiterpene-Proline Conjugates and Phenalenones from sp. CNUFC-EML-48 Using Molecular Networking and Cytotoxicity Profiling.
J Nat Prod
August 2025
Research Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University, Seoul 08826, Republic of Korea.
The use of feature-based molecular networking (FBMN) for metabolomic analysis of the fungal strain sp. CNUFC-EML-48 resulted in the isolation of 17 secondary metabolites. These included four new sesquiterpene-proline conjugates, aculenamides A-D (-), and six new phenalenones (-).
View Article and Find Full Text PDFHigh-throughput screening of small molecules targeting in human iPSC macrophages.
Antimicrob Agents Chemother
July 2025
Global Health Medicines R&D, GlaxoSmithKline, Madrid, Spain.
New treatments are still necessary to eradicate tuberculosis disease. Macrophages derived from human induced pluripotent stem cells (hiPSC-Macs) offer a physiological niche to identify potential new drugs in the context of (Mtb) infection. Here, we describe the scale-up of hiPSC-Macs production in 5-stack chambers for high-throughput drug screening against Mtb.
View Article and Find Full Text PDFMotor and Non-motor Complications Following Different Early Therapies in Parkinson's Disease: Longitudinal Analysis of Real-Life Clinical and Therapeutic Data from the French NS-PARK Cohort.
CNS Drugs
September 2025
Department of Neurology, CIC Neurosciences, Hôpital Pitié-Salpêtrière, Sorbonne Université, Institut du Cerveau-Paris Brain Institute-ICM, Inserm, CNRS, Assistance Publique Hôpitaux de Paris, NS-Park/FCRIN Network, Paris, France.
Background: Levodopa, dopamine agonists (DA) and monoamine oxidase inhibitors (MAOI) are all approved first-line therapies for Parkinson's disease (PD), as monotherapy or in combination. Data on their use in the early management of patients with PD in real-life are lacking. Our objective was to assess the impact of early therapeutic strategies on the development of motor and neuropsychiatric complications using a nationwide PD cohort.
View Article and Find Full Text PDF